Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands

Acta Anaesthesiologica Scandinavica

Volumn 40, Issue 5, 1996, Pages 579-584

  Islander, G ^a   Bendixen, D ^b   Ranklev Twetman, E ^a   Ording H ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

In vitro contracture test; Malignancy hyperthermia susceptibility

Indexed keywords

HALOTHANE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTURE; PARENT; PRIORITY JOURNAL;

EID: 0029955208     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.1996.tb04491.x     Document Type: Article

References (23)

1. Ørding H. Investigation for malignant hyperthermia in Denmark. Thesis. University of Copenhagen: 1995 (in press).
2. McKusick VA. Mendelian inheritance in man. Baltimore: The John Hopkins University Press, 11th ed., 1994:763-766.
3. Ørding H. Incidence of malignant hyperthermia in Denmark. Anesth Analg 1985: 64: 700-704.
4. European Malignant Hyperpyrexia Group. A protocol for investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984: 56: 1267-1269.
5. European Malignant Hyperpyrexia Group. Laboratory diagnosis of malignant hyperpyrexia susceptibility (MHS). Br J Anaesth 1985: 57: 1038.
6. Gillard EF, Otsu K, Fujii J, Khanna VK, De Leon S, Derdemezi J, et al. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of malignant hyperthermia. Genomics 1991: 11: 751-755.
7. Gillard EF, Otsu K, Fujii J, Duff C, De Leon S, Khanna VK, et al. Polymorphisms and deduced amino acid substitution in the coding sequence of the ryanodine receptor (RYR1) gene in individuals with malignant hyperthermia. Genomics 1992: 13: 1247-1254.
8. Quane KA, Healy JMS, Keating KE, Manning BM, Couch FJ, Palmucci LM, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993: 5: 51-55.
9. Quane KA, Keating KE, Manning BM, Healy JMS, Monsieurs K, Heffron JJA, et al. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum Mol Genet 1994: 3: 471-476.
10. Zhang Y, Chen HS, Khanna VK, De Leon S, Phillips MS, Schappert K, et al. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993: 5: 46-50.
11. Fagerlund T, Islander G, Ranklev E, Harbitz I, Hauge JE, Möklebye E, Berg K. Genetic recombination between malignant hyperthermia and calcium release channel in skeletal muscle. Clin Genet 1992: 41: 270-272.
12. Deufel T, Golla A, Iles D, Meindl A, Meitinger T, Schindelhauer D, et al. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility. Am J Hum Genet 1992: 50: 1151-1161.
13. Ranklev-Twetman E. Investigation of malignant hyperthermia in Sweden. Thesis. University of Lund: 1986.
14. Isaacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993: 79: 5-9.
15. Wedel DJ, Nelson TE. Malignant hyperthermia-diagnostic dilemma: false-negative contracture responses with halothane and caffeine alone. Anesth Analg 1994: 78: 787-792.
16. Ørding H, Hedengran HM, Skovgaard KT. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia. Acta Anaesthesiol Scand 1991: 35: 711-716.
17. Islander G, Ranklev Twetman E. Evaluation of anaesthesias in malignant hyperthermia negative patients. Acta Anaesthesiol Scand 1995: 39: 819-821.
18. Ørding H, Bendixen D. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia. Eur J Anaesth 1992: 9: 367-376.
19. Ranklev E, Fletcher R, Blomkvist S. Static versus dynamic in vitro tests in the diagnosis of malignant hyperthermia susceptibility. Br J Anaesth 1986: 58: 646-648.
20. Ørding H, Skovgaard LT. In vitro diagnosis of susceptibility to malignant hyperthermia: comparison between dynamic and static halothane and caffeine tests. Acta Anaesthesiol Scand 1987: 31: 458-461.
21. Mauritz W, Sporn P, Steinbereithner K. Malignant hyperthermia susceptibility confirmed in both parents of probands. Acta Anaesthesiol Scand 1988: 32: 24-26.
22. McPhearson E, Taylor CA. The genetics of malignant hyperthermia: evidence for heterogeneity. Am J Med Genet 1982: 11: 273-285.
23. Kalow W, Sharer S, Britt B. Pharmacogenetics of coffeine and caffeine-halothane contractures in biopsies of human skeletal muscle. Pharmacogenetics 1991: 1: 126-135.